Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Daxor Corporation (DXR)
USD10.56
-0.10 (-0.89%)
US NASDAQ Healthcare Medical - Instruments & Supplies
Address
109 Meco Lane 37830
Oak Ridge, TN, US
Oak Ridge, TN, US
CEO
Michael Richard Feldschuh
Website
daxor.com
IPO
1983-07-25
CIK 27367 ISIN US2394671034
Description
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD10.56
-0.10 (-0.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7.0K
Beta
0.26
Float Shares
2.13M
Free Float %
42.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.10% | -6.55% | -4.81% | -13.32% | -22.71% | -30.31% | +26.91% | +6.57% | +3.01% | +28.50% | +8.21% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
10.56
Low
23.00
+117.9%
Consensus
23.00
+117.9%
Median
23.00
+117.9%
High
23.00
+117.9%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
23.00
+117.9%
|
| All Time | 1 |
23.00
+117.9%
|
Quality scores
Altman Z-Score
254.23
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%-76.4% Q4'25: +59.9% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+1,572.7% ★ Q4'25: +162.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+1,825.7% ★ Q4'25: -225.6% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+1,824.7% ★ Q4'25: +7,237.9% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+20.0% ★ Q4'25: +83.0% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+3.0% Q4'25: +9.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.01× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
Dec 2032 1 Rev. Ana. 1 EPS Ana. |
Dec 2033 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
-115.0K
est: 2.28M (-105.0%)
|
-2.81M
est: 2.00M (-240.3%)
|
-2.62M
est: 14.00M (-118.7%)
|
-353.4K
est: 29.16M (-101.2%)
|
34.59M
est: 50.27M (-31.2%)
|
2.13M
est: 50.27M (-95.8%)
|
503.4K
est: 7.00M (-92.8%)
|
11.90M
11.90M – 11.90M
+70.0% YoY
|
20.80M
20.80M – 20.80M
+74.8% YoY
|
14.00M
14.00M – 14.00M
-32.7% YoY
|
29.16M
29.16M – 29.16M
+108.3% YoY
|
50.27M
50.27M – 50.27M
+72.4% YoY
|
6.70M
6.70M – 6.70M
-86.7% YoY
|
11.90M
11.90M – 11.90M
+77.6% YoY
|
20.80M
20.80M – 20.80M
+74.8% YoY
|
| EBITDA |
-495.7K
est: -187.5K (-164.4%)
|
-1.72M
est: -164.3K (-948.0%)
|
4.75M
est: -1.15M (+512.7%)
|
6.11M
est: -2.40M (+355.0%)
|
329.7K
est: -4.13M (+108.0%)
|
2.06M
est: -247.1K (+933.1%)
|
9.19M
est: -34.4K (+26,801.9%)
|
-58.5K
-58.5K – -58.5K
-70.0% YoY
|
-102.2K
-102.2K – -102.2K
-74.8% YoY
|
-68.8K
-68.8K – -68.8K
+32.7% YoY
|
-143.3K
-143.3K – -143.3K
-108.3% YoY
|
-247.1K
-247.1K – -247.1K
-72.4% YoY
|
-32.9K
-32.9K – -32.9K
+86.7% YoY
|
-58.5K
-58.5K – -58.5K
-77.6% YoY
|
-102.2K
-102.2K – -102.2K
-74.8% YoY
|
| EBIT |
-495.7K
est: -501.8K (+1.2%)
|
-1.72M
est: -439.9K (-291.5%)
|
4.77M
est: -3.08M (+254.8%)
|
5.25M
est: -6.41M (+181.9%)
|
329.7K
est: -11.06M (+103.0%)
|
621.4K
est: -7.17M (+108.7%)
|
9.19M
est: -998.9K (+1,019.6%)
|
-1.70M
-1.70M – -1.70M
-70.0% YoY
|
-2.97M
-2.97M – -2.97M
-74.8% YoY
|
-2.00M
-2.00M – -2.00M
+32.7% YoY
|
-4.16M
-4.16M – -4.16M
-108.3% YoY
|
-7.17M
-7.17M – -7.17M
-72.4% YoY
|
-956.1K
-956.1K – -956.1K
+86.7% YoY
|
-1.70M
-1.70M – -1.70M
-77.6% YoY
|
-2.97M
-2.97M – -2.97M
-74.8% YoY
|
| Net Income |
-495.7K
est: 387.4K (-228.0%)
|
-1.71M
est: 726.4K (-334.8%)
|
4.75M
est: 1.94M (+145.1%)
|
5.18M
est: 4.84M (+6.9%)
|
280.6K
est: 8.72M (-96.8%)
|
536.3K
est: 8.97M (-94.0%)
|
9.17M
est: -199.4K (+4,698.4%)
|
-1.05M
-1.05M – -1.05M
-425.0% YoY
|
-149.6K
-149.6K – -149.6K
+85.7% YoY
|
1.99M
1.99M – 1.99M
+1,433.3% YoY
|
4.99M
4.99M – 4.99M
+150.0% YoY
|
8.97M
8.97M – 8.97M
+80.0% YoY
|
-249.3K
-249.3K – -249.3K
-102.8% YoY
|
-1.05M
-1.05M – -1.05M
-320.0% YoY
|
-149.6K
-149.6K – -149.6K
+85.7% YoY
|
| SGA |
384.2K
est: -1.60M (+124.0%)
|
593.5K
est: -1.41M (+142.2%)
|
991.3K
est: -9.84M (+110.1%)
|
1.09M
est: -20.50M (+105.3%)
|
307.4K
est: -35.35M (+100.9%)
|
294.2K
est: -33.22M (+100.9%)
|
—
est: -4.63M (+100.0%)
|
-7.86M
-7.86M – -7.86M
-70.0% YoY
|
-13.74M
-13.74M – -13.74M
-74.8% YoY
|
-9.25M
-9.25M – -9.25M
+32.7% YoY
|
-19.27M
-19.27M – -19.27M
-108.3% YoY
|
-33.22M
-33.22M – -33.22M
-72.4% YoY
|
-4.43M
-4.43M – -4.43M
+86.7% YoY
|
-7.86M
-7.86M – -7.86M
-77.6% YoY
|
-13.74M
-13.74M – -13.74M
-74.8% YoY
|
| EPS |
-0.12
est: 0.08 (-250.0%)
|
-0.43
est: 0.15 (-386.7%)
|
1.18
est: 0.40 (+195.0%)
|
0.60
est: 1.00 (-40.0%)
|
0.06
est: 1.80 (-96.6%)
|
0.11
est: 1.80 (-93.9%)
|
1.84
est: -0.04 (+4,700.0%)
|
-0.21
-0.21 – -0.21
-425.0% YoY
|
-0.03
-0.03 – -0.03
+85.7% YoY
|
0.40
0.40 – 0.40
+1,433.3% YoY
|
1.00
1.00 – 1.00
+150.0% YoY
|
1.80
1.80 – 1.80
+80.0% YoY
|
-0.05
-0.05 – -0.05
-102.8% YoY
|
-0.21
-0.21 – -0.21
-320.0% YoY
|
-0.03
-0.03 – -0.03
+85.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 4/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
937.1K
OE per share TTM
0.25
Owner's Yield
1.80%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
-17.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
4.07M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
+6 vs prev Q
New positions
8
Closed positions
2
Increased
8
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 12.5K +12.5K (+100.0%) | 184.38M +184.4M (+100.0%) | 0.25% +0.251 pp | 0.16% +0.157 pp | USD14.75 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 49.0K +— (+0.0%) | 723.2K +56.9K (+8.5%) | 0.98% +0.000 pp | 0.00% +0.000 pp | USD14.28 +3.3% | 23 qtrs — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 28.2K -700.0 (-2.4%) | 416.3K +18.2K (+4.6%) | 0.57% -0.014 pp | 0.00% +0.000 pp | USD10.97 +34.5% | 76 qtrs — |
| 4 | MORGAN STANLEY | 3.2K -300.0 (-8.5%) | 47.7K -941.0 (-1.9%) | 0.06% -0.006 pp | 0.00% +0.000 pp | USD9.74 +51.4% | 21 qtrs — |
| 5 | SBI SECURITIES CO., LTD. | 3.1K +— (+0.0%) | 46.1K +3.1K (+7.2%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD7.69 +91.8% | 5 qtrs — |
| 6 | ADVISOR GROUP HOLDINGS, INC. | 500.00 +500.0 (+100.0%) | 7.4K +7.4K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD14.75 +0.0% | 6 qtrs — |
| 7 | UBS GROUP AG | 90.00 +90.0 (+100.0%) | 1.3K +1.3K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD14.74 +0.1% | 1 qtrs NEW |
| 8 | JPMORGAN CHASE & CO | 5.00 +1.0 (+25.0%) | 74.00 +20.0 (+37.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.00 +47.5% | 10 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | — -40.0 (-100.0%) | — -551.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 10 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 223.72 | 0.17% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.1K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.0K | 0.17% |
| 4 | Vanguard Total Stock Market ETF VTI | 0.00% | 517.7K | 0.03% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.1K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 617.36 | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 249.56 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 27.50 | 0.22% |
| 9 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 3.88 | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 4.57 | 0.31% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
1.0K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+1,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 1,000 | 9.07 | 9.1K | 213,694 | D | ↗ |
| 2026-03-31 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 1,000 | 9.90 | 9.9K | 21,050 | D | ↗ |
| 2026-03-20 | Jefferies John | Officer | P-Purchase | A | Daxor Common Stock | 2,285 | 0.00 | — | 23,557 | D | ↗ |
| 2025-12-09 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 3,000 | 0.00 | — | 20,050 | D | ↗ |
| 2025-12-09 | Feldschuh Jonathan Adam | Director / Officer | P-Purchase | A | Daxor Common Stock | 18,000 | 0.00 | — | 53,908 | D | ↗ |
| 2025-11-12 | Jefferies John | Officer | P-Purchase | A | Daxor Common Stock | 2,344 | 0.00 | — | 17,616 | D | ↗ |
| 2025-09-30 | Jefferies John | Officer | — | — | Stock Options (right to buy) | 353 | 11.68 | 4.1K | 0 | D | ↗ |
| 2025-06-24 | Goudie Joy S. | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.29 | 23.2K | 2,500 | D | ↗ |
| 2025-06-24 | Feuer Edward | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.29 | 23.2K | 2,500 | D | ↗ |
| 2025-06-24 | DesRosiers Caleb | Director | A-Award | A | Stock options (right to buy) | 2,500 | 9.29 | 23.2K | 2,500 | D | ↗ |
| 2025-06-24 | Cremisi Henry D. | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.29 | 23.2K | 2,500 | D | ↗ |
| 2025-04-04 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 2,063 | 7.89 | 16.3K | 212,694 | D | ↗ |
| 2025-03-10 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 1,000 | 8.00 | 8.0K | 17,050 | D | ↗ |
| 2025-03-10 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 3,360 | 7.68 | 25.8K | 210,852 | D | ↗ |
| 2024-12-06 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 45,000 | 0.00 | — | 207,492 | D | ↗ |
| 2024-12-06 | Feldschuh Jonathan Adam | Director / Officer | P-Purchase | A | Daxor Common Stock | 32,000 | 0.00 | — | 35,908 | D | ↗ |
| 2024-07-15 | Goudie Joy S. | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.20 | 23.0K | 2,500 | — | ↗ |
| 2024-07-15 | Feuer Edward | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.20 | 23.0K | 2,500 | — | ↗ |
| 2024-07-15 | DesRosiers Caleb | Director | A-Award | A | Stock options (right to buy) | 2,500 | 9.20 | 23.0K | 2,500 | — | ↗ |
| 2024-07-15 | Cremisi Henry D. | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.20 | 23.0K | 2,500 | — | ↗ |
| 2024-03-27 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 750 | 8.70 | 6.5K | 11,300 | — | ↗ |
| 2024-03-26 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 1,000 | 8.13 | 8.1K | 210,631 | D | ↗ |
| 2024-03-19 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 647 | 8.15 | 5.3K | 209,631 | D | ↗ |
| 2024-03-10 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 1,492 | 7.72 | 11.5K | 208,984 | D | ↗ |
| 2024-03-04 | Feuer Edward | Director | P-Purchase | A | Daxor Common Stock | 1,000 | 7.21 | 7.2K | 1,000 | — | ↗ |
| 2023-12-06 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 120 | 7.75 | 930.00 | 10,550 | — | ↗ |
| 2023-12-01 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 180 | 7.75 | 1.4K | 10,430 | — | ↗ |
| 2023-12-01 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 800 | 7.80 | 6.2K | 162,492 | — | ↗ |
| 2023-11-24 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 500 | 7.94 | 4.0K | 10,250 | — | ↗ |
| 2023-11-21 | Feldschuh Michael Richard | Director / Officer | A-Award | A | Daxor Common Stock | 84 | 7.65 | 642.60 | 160,692 | — | ↗ |
| 2023-11-10 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 1,001 | 7.83 | 7.8K | 161,608 | — | ↗ |
| 2023-11-09 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 401 | 7.85 | 3.1K | 160,607 | — | ↗ |
| 2023-10-31 | Michel Robert J | Officer | A-Award | A | Daxor Common Stock | 2,000 | 0.00 | — | 9,750 | — | ↗ |
| 2023-10-13 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 500 | 9.02 | 4.5K | 7,750 | — | ↗ |
| 2023-09-18 | Estate of Joseph Feldschuh | 10% Owner | G-Gift | D | Common Stock | 25,000 | 0.00 | — | 2,549,455 | — | ↗ |
| 2023-07-11 | Michel Robert J | Officer | A-Award | A | Stock Options (right to buy) | 14,000 | 9.88 | 138.3K | 14,000 | — | ↗ |
| 2023-07-11 | LOMBARD JAMES A | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.88 | 24.7K | 2,500 | — | ↗ |
| 2023-07-11 | Goudie Joy S. | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.88 | 24.7K | 2,500 | — | ↗ |
| 2023-07-11 | Feuer Edward | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.88 | 24.7K | 2,500 | — | ↗ |
| 2023-07-11 | Feldschuh Michael Richard | Director / Officer | A-Award | A | Stock Options (right to buy) | 30,000 | 9.88 | 296.4K | 30,000 | — | ↗ |
| 2023-07-11 | Feldschuh Jonathan Adam | Director / Officer | A-Award | A | Stock Options (right to buy) | 25,000 | 9.88 | 247.0K | 25,000 | — | ↗ |
| 2023-07-11 | DesRosiers Caleb | Director | A-Award | A | Stock options (right to buy) | 2,500 | 9.88 | 24.7K | 2,500 | — | ↗ |
| 2023-07-11 | Cremisi Henry D. | Director | A-Award | A | Stock Options (right to buy) | 2,500 | 9.88 | 24.7K | 2,500 | — | ↗ |
| 2023-05-24 | Goudie Joy S. | Director | P-Purchase | A | Common Stock | 300 | 9.75 | 2.9K | 300 | — | ↗ |
| 2023-05-24 | Feldschuh Michael Richard | Officer | P-Purchase | A | Common Stock | 2,000 | 9.75 | 19.5K | 160,206 | — | ↗ |
| 2023-03-27 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 4,750 | 0.00 | — | 15,050 | D | ↗ |
| 2022-11-18 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 1,000 | 10.00 | 10.0K | 7,250 | — | ↗ |
| 2022-11-17 | DesRosiers Caleb | Director | P-Purchase | A | Daxor Common Stock | 3,157 | 9.50 | 30.0K | 3,157 | — | ↗ |
| 2022-06-23 | LOMBARD JAMES A | Director | A-Award | A | STOCK OPTION (right to buy) | 2,000 | 13.09 | 26.2K | 2,000 | — | ↗ |
| 2022-06-23 | Goudie Joy S. | Director | A-Award | A | STOCK OPTIONS (right to buy) | 2,000 | 13.09 | 26.2K | 2,000 | — | ↗ |
| 2022-06-23 | Feuer Edward | Director | A-Award | A | Stock Options (right to buy) | 2,000 | 13.09 | 26.2K | 2,000 | — | ↗ |
| 2022-06-23 | DesRosiers Caleb | Director | A-Award | A | Stock options (right to buy) | 4,000 | 0.00 | — | 4,000 | — | ↗ |
| 2022-06-23 | Cremisi Henry D. | Director | A-Award | A | STOCK OPTION (right to buy) | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2022-01-18 | DesRosiers Caleb | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-24 | LOMBARD JAMES A | Director | A-Award | A | STOCK OPTION (right to buy) | 2,100 | 10.82 | 22.7K | 2,100 | — | ↗ |
| 2021-06-24 | Goudie Joy S. | Director | A-Award | A | STOCK OPTIONS (right to buy) | 2,100 | 10.82 | 22.7K | 2,100 | — | ↗ |
| 2021-06-24 | Feuer Edward | Director | A-Award | A | STOCK OPTION (right to buy) | 2,100 | 10.82 | 22.7K | 2,100 | — | ↗ |
| 2021-06-24 | Cremisi Henry D. | Director | A-Award | A | STOCK OPTION (right to buy) | 2,000 | 10.82 | 21.6K | 2,000 | — | ↗ |
| 2021-06-10 | Michel Robert J | Officer | A-Award | A | Daxor Common Stock | 2,000 | 0.00 | — | 6,250 | — | ↗ |
| 2021-04-19 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 1,000 | 10.25 | 10.3K | 4,250 | — | ↗ |
| 2021-04-16 | Feldschuh Michael Richard | Officer | P-Purchase | A | Common Stock | 4,200 | 10.33 | 43.4K | 158,206 | — | ↗ |
| 2020-07-22 | Feuer Edward | Director | D-Return | D | DAXOR COMMON STOCK | 1,500 | 19.21 | 28.8K | 0 | — | ↗ |
| 2020-07-22 | Estate of Joseph Feldschuh | 10% Owner | D-Return | D | DAXOR CORPORATION COMMON STOCK | 225,000 | 20.00 | 4.50M | 2,549,455 | — | ↗ |
| 2020-06-29 | Goudie Joy S. | Director | A-Award | A | STOCK OPTIONS ( right to buy ) | 2,000 | 13.06 | 26.1K | 2,000 | — | ↗ |
| 2020-06-25 | WOLPOFF MARTIN S | Director | A-Award | A | STOCK OPTION (right to buy) | 2,000 | 14.11 | 28.2K | 2,000 | — | ↗ |
| 2020-06-25 | Saxe Bernhard | Director | A-Award | A | STOCK OPTION (right to buy) | 2,000 | 14.11 | 28.2K | 2,000 | — | ↗ |
| 2020-06-25 | Michel Robert J | Officer | A-Award | A | STOCK OPTION (right to buy) | 10,000 | 14.11 | 141.1K | 10,000 | — | ↗ |
| 2020-06-25 | LOMBARD JAMES A | Director | A-Award | A | STOCK OPTION (right to buy) | 2,000 | 14.11 | 28.2K | 2,000 | — | ↗ |
| 2020-06-25 | Feuer Edward | Director | A-Award | A | STOCK OPTION (right to buy) | 2,000 | 14.11 | 28.2K | 2,000 | — | ↗ |
| 2020-06-25 | Feldschuh Michael Richard | Director / Officer | A-Award | A | STOCK OPTION (right to buy) | 25,000 | 14.11 | 352.8K | 25,000 | — | ↗ |
| 2020-06-25 | Feldschuh Jonathan Adam | Director / Officer | A-Award | A | STOCK OPTION (right to buy) | 20,000 | 14.11 | 282.2K | 20,000 | — | ↗ |
| 2020-06-25 | Cremisi Henry D. | Director | A-Award | A | STOCK OPTION (right to buy) | 18,000 | 13.94 | 250.9K | 18,000 | — | ↗ |
| 2019-08-01 | Cremisi Henry D. | Director | — | D | STOCK OPTION (right to buy) | 5,000 | 9.00 | 45.0K | 0 | — | ↗ |
| 2019-03-22 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 750 | 13.02 | 9.8K | 3,250 | — | ↗ |
| 2019-03-21 | Feldschuh Michael Richard | Officer | P-Purchase | A | Common Stock | 200 | 12.20 | 2.4K | 154,006 | — | ↗ |
| 2018-11-07 | Michel Robert J | Officer | P-Purchase | A | Daxor Common Stock | 750 | 13.02 | 9.8K | 3,250 | — | ↗ |
| 2018-09-28 | Michel Robert J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-07-31 | Thompson Soren | Officer | P-Purchase | D | Daxor Common Stock | 1,000 | 5.50 | 5.5K | 1,950 | — | ↗ |
| 2018-07-13 | Feuer Edward | Director | P-Purchase | A | Daxor Common Stock | 1,500 | 6.18 | 9.3K | 1,500 | — | ↗ |
| 2018-03-15 | Thompson Soren | Officer | S-Sale | D | Daxor Common Stock | 2,950 | 19.54 | 57.6K | 950 | — | ↗ |
| 2018-03-15 | Feldschuh Michael Richard | Director / Officer | S-Sale | D | Daxor Common Stock | 20,800 | 16.40 | 341.1K | 152,806 | — | ↗ |
| 2018-03-15 | Feldschuh Jonathan Adam | Director | S-Sale | D | Daxor Common Stock | 19,194 | 18.63 | 357.6K | 3,908 | — | ↗ |
| 2018-03-09 | FELDSCHUH JOSEPH | 10% Owner | S-Sale | D | Daxor Common Stock | 37,000 | 6.44 | 238.3K | 2,774,455 | — | ↗ |
| 2018-01-31 | Estate of Joseph Feldschuh | Director | — | D | DAXOR COMMON STOCK | 0 | 0.00 | — | 2,774,455 | — | ↗ |
| 2017-10-17 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 2 | 4.66 | 9.32 | 172,799 | — | ↗ |
| 2017-10-16 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 148 | 4.95 | 732.60 | 172,797 | — | ↗ |
| 2017-10-13 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 3 | 4.95 | 14.85 | 172,649 | — | ↗ |
| 2017-10-12 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 49 | 4.95 | 242.55 | 172,646 | — | ↗ |
| 2017-09-05 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 100 | 5.40 | 540.00 | 173,097 | — | ↗ |
| 2017-08-25 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 200 | 5.56 | 1.1K | 172,997 | — | ↗ |
| 2017-08-24 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 200 | 5.63 | 1.1K | 172,797 | — | ↗ |
| 2017-06-28 | Thompson Soren | Officer | P-Purchase | A | Daxor Common Stock | 500 | 6.50 | 3.3K | 3,900 | — | ↗ |
| 2017-05-19 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 212 | 6.72 | 1.4K | 172,597 | — | ↗ |
| 2017-05-11 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Daxor Common Stock | 302 | 8.50 | 2.6K | 172,385 | — | ↗ |
| 2017-03-17 | Thompson Soren | Officer | — | D | Daxor Corporation | 0 | 0.00 | — | 3,400 | — | ↗ |
| 2017-01-04 | Feldschuh Michael Richard | Director / Officer | G-Gift | A | DAXOR COMMON STOCK | 74,400 | 8.50 | 632.4K | 172,385 | — | ↗ |
| 2017-01-04 | FELDSCHUH JOSEPH | Officer / 10% Owner | S-Sale | D | DAXOR Common Stock | 48,500 | 8.50 | 412.3K | 2,961,982 | — | ↗ |
| 2016-04-17 | Feldschuh Michael Richard | Director / Officer | G-Gift | A | Common Stock | 41,700 | 0.00 | — | 57,783 | — | ↗ |
| 2016-04-17 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 150,400 | 0.00 | — | 2,886,982 | — | ↗ |
| 2016-04-15 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 100 | 8.06 | 806.00 | 58,083 | — | ↗ |
| 2016-04-14 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 200 | 8.07 | 1.6K | 16,083 | — | ↗ |
| 2016-04-13 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 200 | 8.06 | 1.6K | 57,983 | — | ↗ |
| 2016-04-11 | Feldschuh Michael Richard | Officer | P-Purchase | A | Common Stock | 200 | 8.06 | 1.6K | 15,883 | — | ↗ |
| 2016-04-07 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 100 | 8.08 | 808.00 | 15,683 | — | ↗ |
| 2015-08-12 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 500 | 6.22 | 3.1K | 15,583 | — | ↗ |
| 2015-08-06 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 100 | 6.63 | 663.00 | 14,983 | — | ↗ |
| 2015-08-04 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 100 | 6.63 | 663.00 | 14,883 | — | ↗ |
| 2015-08-03 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 483 | 6.46 | 3.1K | 14,783 | — | ↗ |
| 2015-07-28 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 500 | 6.48 | 3.2K | 14,300 | — | ↗ |
| 2015-07-24 | Feldschuh Michael Richard | Director / Officer | P-Purchase | A | Common Stock | 300 | 6.70 | 2.0K | 13,800 | — | ↗ |
| 2015-04-10 | Meegan Diane Marie | Officer | S-Sale | D | Common Stock | 1,000 | 7.69 | 7.7K | 500 | — | ↗ |
| 2015-04-01 | FELDSCHUH JOSEPH | Officer | P-Purchase | A | Common Stock | 300 | 5.66 | 1.7K | 2,736,582 | — | ↗ |
| 2015-03-24 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 5.60 | 1.7K | 2,736,282 | — | ↗ |
| 2015-03-20 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 105 | 5.61 | 589.05 | 2,735,982 | — | ↗ |
| 2015-03-16 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 5.75 | 5.8K | 2,734,682 | — | ↗ |
| 2015-03-12 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 500 | 6.05 | 3.0K | 2,732,682 | — | ↗ |
| 2015-02-19 | Meegan Diane Marie | Officer | P-Purchase | A | Common Stock | 1,000 | 5.91 | 5.9K | 1,500 | — | ↗ |
| 2015-02-19 | Feldschuh Michael Richard | Director | P-Purchase | A | Daxor Common Stock | 300 | 5.90 | 1.8K | 13,300 | — | ↗ |
| 2015-02-19 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 5.89 | 5.9K | 2,732,182 | — | ↗ |
| 2015-02-09 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500 | 5.94 | 3.0K | 2,730,682 | — | ↗ |
| 2015-01-29 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500 | 6.15 | 3.1K | 2,729,482 | — | ↗ |
| 2015-01-26 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 200 | 6.78 | 1.4K | 2,728,982 | — | ↗ |
| 2015-01-15 | Feldschuh Michael Richard | Director | P-Purchase | A | Daxor Common Stock | 291 | 6.27 | 1.8K | 12,800 | — | ↗ |
| 2014-12-18 | Feldschuh Michael Richard | Director | P-Purchase | A | Daxor Common Stock | 500 | 6.50 | 3.3K | 11,800 | — | ↗ |
| 2014-12-03 | Feldschuh Michael Richard | Director | P-Purchase | A | Daxor Common Stock | 500 | 6.12 | 3.1K | 11,300 | — | ↗ |
| 2014-11-26 | Feldschuh Michael Richard | Director | P-Purchase | A | Daxor Common Stock | 1,300 | 6.09 | 7.9K | 10,800 | — | ↗ |
| 2014-11-26 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.70 | 2.0K | 3,128,782 | — | ↗ |
| 2014-11-07 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.44 | 1.9K | 3,128,482 | — | ↗ |
| 2014-10-13 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 175 | 5.93 | 1.0K | 3,128,057 | — | ↗ |
| 2014-10-08 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 100 | 6.10 | 610.00 | 3,127,882 | — | ↗ |
| 2014-10-07 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.08 | 1.8K | 3,127,782 | — | ↗ |
| 2014-09-30 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.45 | 1.9K | 3,127,482 | — | ↗ |
| 2014-09-29 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.48 | 1.9K | 3,127,182 | — | ↗ |
| 2014-09-16 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.54 | 2.0K | 3,126,882 | — | ↗ |
| 2014-09-12 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.79 | 2.0K | 3,126,582 | — | ↗ |
| 2014-09-09 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.81 | 2.0K | 3,126,282 | — | ↗ |
| 2014-09-05 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 7.00 | 2.1K | 3,125,982 | — | ↗ |
| 2014-08-22 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 200 | 6.87 | 1.4K | 3,125,519 | — | ↗ |
| 2014-06-17 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 6.48 | 1.9K | 3,125,319 | — | ↗ |
| 2014-06-13 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 302 | 7.30 | 2.2K | 3,125,019 | — | ↗ |
| 2014-04-23 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 8.06 | 2.4K | 3,124,717 | — | ↗ |
| 2014-04-22 | Saxe Bernhard | Director | P-Purchase | A | Daxor Common Stock | 200 | 8.06 | 1.6K | 200 | — | ↗ |
| 2014-04-11 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 100 | 8.30 | 830.00 | 3,124,417 | — | ↗ |
| 2014-04-01 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 8.29 | 2.5K | 3,124,317 | — | ↗ |
| 2014-03-07 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 200 | 7.60 | 1.5K | 3,124,017 | — | ↗ |
| 2014-03-05 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 500 | 6.90 | 3.5K | 3,123,817 | — | ↗ |
| 2014-03-03 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 503 | 7.05 | 3.5K | 3,123,317 | — | ↗ |
| 2014-02-28 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 192 | 7.20 | 1.4K | 3,122,317 | — | ↗ |
| 2014-02-27 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 8 | 7.20 | 57.60 | 3,122,125 | — | ↗ |
| 2014-02-26 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 300 | 7.20 | 2.2K | 3,122,117 | — | ↗ |
| 2014-02-14 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 400 | 7.29 | 2.9K | 3,121,817 | — | ↗ |
| 2014-02-12 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 7.36 | 7.4K | 3,121,417 | — | ↗ |
| 2014-02-10 | FELDSCHUH JOSEPH | Officer | P-Purchase | A | Daxor Common Stock | 500 | 6.75 | 3.4K | 3,120,117 | — | ↗ |
| 2014-01-21 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 514 | 6.75 | 3.5K | 3,118,617 | — | ↗ |
| 2014-01-03 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 404 | 6.80 | 2.7K | 3,118,103 | — | ↗ |
| 2013-12-24 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 83 | 6.80 | 564.40 | 3,117,699 | — | ↗ |
| 2013-12-20 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 290 | 6.90 | 2.0K | 3,117,616 | — | ↗ |
| 2013-12-16 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 210 | 6.90 | 1.4K | 3,117,326 | — | ↗ |
| 2013-12-13 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 420 | 7.00 | 2.9K | 3,117,116 | — | ↗ |
| 2013-12-12 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 80 | 7.00 | 560.00 | 3,116,195 | — | ↗ |
| 2013-10-07 | Feldschuh Michael Richard | Director | — | D | Common Stock | 0 | 0.00 | — | 9,500 | — | ↗ |
| 2013-09-10 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,027 | 6.85 | 7.0K | 3,116,115 | — | ↗ |
| 2013-08-26 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 974 | 6.95 | 6.8K | 4,087,114 | — | ↗ |
| 2013-08-09 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 7.05 | 7.1K | 3,113,114 | — | ↗ |
| 2013-07-09 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 365 | 7.15 | 2.6K | 3,112,114 | — | ↗ |
| 2013-06-10 | FELDSCHUH JOSEPH | Director / Officer | P-Purchase | A | Daxor Common Stock | 635 | 7.15 | 4.5K | 3,110,799 | — | ↗ |
| 2013-05-09 | WILLENS ROBERT | Director | P-Purchase | A | Daxor Common Stock | 1,000 | 7.26 | 7.3K | 18,164 | — | ↗ |
| 2013-03-19 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 7.15 | 7.2K | 3,110,164 | — | ↗ |
| 2013-03-14 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 358 | 7.35 | 2.6K | 3,107,522 | — | ↗ |
| 2013-03-08 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 115 | 7.45 | 856.75 | 3,107,164 | — | ↗ |
| 2013-03-07 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 15 | 7.45 | 111.75 | 3,107,049 | — | ↗ |
| 2013-03-06 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 200 | 7.45 | 1.5K | 3,107,034 | — | ↗ |
| 2013-03-04 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 220 | 7.45 | 1.6K | 3,106,834 | — | ↗ |
| 2013-02-28 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 7.45 | 7.5K | 3,106,614 | — | ↗ |
| 2013-02-27 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 250 | 7.45 | 1.9K | 3,105,614 | — | ↗ |
| 2013-02-26 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 194 | 7.45 | 1.4K | 3,105,364 | — | ↗ |
| 2013-02-06 | FELDSCHUH JOSEPH | Officer | P-Purchase | A | Daxor Common Stock | 906 | 7.60 | 6.9K | 3,105,170 | — | ↗ |
| 2013-01-29 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 600 | 7.65 | 4.6K | 3,104,264 | — | ↗ |
| 2013-01-08 | FELDSCHUH JOSEPH | Officer | P-Purchase | A | Daxor Common Stock | 1,595 | 7.55 | 12.0K | 3,103,632 | — | ↗ |
| 2012-12-18 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 333 | 7.60 | 2.5K | 3,102,037 | — | ↗ |
| 2012-12-14 | FELDSCHUH JOSEPH | Officer | P-Purchase | A | Daxor Corp. | 456 | 7.65 | 3.5K | 3,101,299 | — | ↗ |
| 2012-12-12 | WILLENS ROBERT | Director | P-Purchase | A | Daxor Common Stock | 1,000 | 7.70 | 7.7K | 17,164 | — | ↗ |
| 2012-12-07 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 711 | 7.65 | 5.4K | 3,100,843 | — | ↗ |
| 2012-12-03 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 857 | 7.75 | 6.6K | 3,100,097 | — | ↗ |
| 2012-11-27 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 529 | 7.75 | 4.1K | 3,099,240 | — | ↗ |
| 2012-10-16 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 991 | 7.95 | 7.9K | 3,098,711 | — | ↗ |
| 2012-10-12 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 9 | 7.95 | 71.55 | 3,097,720 | — | ↗ |
| 2012-10-08 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 2,000 | 8.00 | 16.0K | 3,097,711 | — | ↗ |
| 2012-09-25 | WILLENS ROBERT | Director | P-Purchase | A | Daxor Common Stock | 1,859 | 8.30 | 15.4K | 16,164 | — | ↗ |
| 2012-09-24 | WILLENS ROBERT | Director | P-Purchase | A | Daxor Common Stock | 141 | 8.26 | 1.2K | 14,305 | — | ↗ |
| 2012-09-21 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 8.60 | 8.6K | 3,094,711 | — | ↗ |
| 2012-09-10 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 8.70 | 8.7K | 3,092,711 | — | ↗ |
| 2012-09-04 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,299 | 8.78 | 11.4K | 3,091,711 | — | ↗ |
| 2012-08-23 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 350 | 8.80 | 3.1K | 3,090,412 | — | ↗ |
| 2012-08-17 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,000 | 8.85 | 8.9K | 3,090,062 | — | ↗ |
| 2012-08-16 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 400 | 8.70 | 3.5K | 3,089,062 | — | ↗ |
| 2012-08-14 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 1,824 | 8.80 | 16.1K | 3,088,662 | — | ↗ |
| 2012-08-10 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 83 | 8.85 | 734.55 | 3,086,838 | — | ↗ |
| 2012-07-20 | FELDSCHUH JOSEPH | Officer | P-Purchase | A | Daxor Common Stock | 176 | 8.80 | 1.5K | 3,086,755 | — | ↗ |
| 2012-06-26 | FELDSCHUH JOSEPH | Director / Officer / 10% Owner | P-Purchase | A | Daxor Common Stock | 111 | 8.85 | 982.35 | 3,086,579 | — | ↗ |
Executive team
Top executives
EBIT / Employee
2.5K
Shares Outstanding
5.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Lynn Jefferies FACC | Chief Medical Officer | 160.6K | — |
| Robert J. Michel | Chief Financial Officer, Chief Compliance Officer & Corporate Secretary | 151.5K | male |
| Jonathan Adam Feldschuh | Chief Scientific Officer & Director | 129.2K | male |
| Michael Richard Feldschuh | Chairman, President & Chief Executive Officer | 101.0K | male |
| Kathryn A. Kornafel | Senior Vice President of Marketing & Commercial Development | — | female |
| Linda Cooper | Vice President of Development & Operations | — | female |
ESG Rating
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DXR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
